KB LAMINATES
01888
CHINA CINDA
01359
CHINAHONGQIAO
01378
DONGFENG GROUP
00489
U-PRESID CHINA
00220
HK Stock MarketDetailed Quotes
02179 RECBIO-B
- 8.450
- +0.220+2.67%
Market Closed Dec 27 16:08 CST
4.08BMarket Cap-6.79P/E (TTM)
8.440High8.100Low10.00KVolume8.230Open8.230Pre Close83.99KTurnover0.00%Turnover RatioLossP/E (Static)482.96MShares10.86052wk High4.45P/B2.67BFloat Cap7.30052wk Low--Dividend TTM316.14MShs Float28.300Historical High--Dividend LFY4.13%Amplitude7.300Historical Low8.399Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
About RECBIO-B Company
Jiangsu Ruike Biotechnology Co., Ltd. (“Recobiology” or the “Company”) is an innovative vaccine company dedicated to developing and commercializing safer and more effective innovative vaccines to address far unmet public health needs. Recobiotics has a high-value vaccine portfolio, which is driven by novel adjuvant technology and protein engineering technology developed independently. Through the company's strong R&D capabilities, it has established a powerful innovative vaccine portfolio composed of 11 vaccine candidates, and from a strategic perspective, the coverage has been extended to 5 of the 10 most burdensome diseases in the “Global Burden of Disease” assessed by DALYs issued by the World Health Organization in 2019, and the disease fields covered by 3 of the 5 best-selling vaccine products in the world in 2020. Currently, the company's core product, REC603, a recombinant HPV nine-valent vaccine, is currently in phase III clinical trials. The company has formulated clear commercialization strategies in China and overseas, with the aim of further penetrating diversified markets around the world. At the same time, the company has developed three advanced technology platforms for novel adjuvant development, protein engineering, and immune evaluation. Such platforms enable the company to continuously discover and develop innovative vaccines and apply advanced technology in vaccine candidates. The company completed Series A financing in 2019, Series B financing in 2020, and Series B+ and Series C financing respectively in 2021.
Company Profile
Symbol02179
Company NameRECBIO-B
ISINCNE1000057K9
Listing DateMar 31, 2022
Issue Price24.80
Shares Offered30.85M share(s)
FoundedMay 18, 2012
Registered AddressChina
Chairmanyong liu
Secretaryqingqingwengmeiyi chen
Audit InstitutionErnst & Young
Company CategoryMainland registration of Mainland Individuals control
Registered OfficeNo. 888, Yaocheng Avenue, Taizhou Pharmaceutical High-tech Zone
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees507
MarketHong Kong motherboard
Phone(0523)88820888
Fax(86)(523)86818860
Emailmedia@recbio.cn
Websitehttp://www.recbio.cn
Business Jiangsu Ruike Biotechnology Co., Ltd. is a Chinese company engaged in vaccine research and development. The company has a range of clinical and pre-clinical vaccines. The human papillomavirus (HPV) vaccine pipeline includes the recombinant HPV nine valent vaccine candidate REC603, the recombinant HPV bivalent vaccine REC601 and REC602, the recombinant HPV quadrivalent vaccine REC604a, and the recombinant HPV nine valent vaccine REC604b. The company is also involved in COVID-19 vaccine research and development. The company mainly sells its products in the domestic market.
Company Executives
- Name
- Position
- Salary
- yong liu
- Chairman of the Board, Executive Director, General Manager, Chairman of the Nomination Committee, Authorized Representative
- 14.52M
- bu li
- Executive Director, Deputy General Manager, Remuneration Committee Members, Authorized Representative
- 3.16M
- qingqing chen
- Executive Director, Deputy General Manager, Chief Financial Officer, Joint Company Secretary, Board Secretary
- 9.90M
- kunxue hong
- Executive Director
- 2.38M
- hongbin zhou
- Non-executive Directors, Audit Committee Members
- --
- ruwei wang
- Non-executive Directors
- --
- jiaxin zhang
- Non-executive Directors
- --
- houwei hu
- Non-executive Directors
- --
- guodong liang
- Independent Non-Executive Director, Nomination Committee Members, Remuneration Committee Members
- 290.00K
- lijun xia
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Remuneration Committee Members
- 290.00K
- GAO Feng
- Independent Non-Executive Director, Remuneration Committee Members, Nomination Committee Members
- 290.00K
- minghui yuan
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members
- 288.00K
- weiwei qiao
- Chairman of the Supervisory Board
- --
- feizhou wang
- Auditors
- --
- ranting qian
- Auditors
- --
- ping liu
- Employee Representative Supervisor
- --
- lei zhou
- Chief Financial Officer
- --
- meiyi weng
- Joint Company Secretary, Legal Process Document Agent
- --
- jianping chen
- Deputy General Manager
- 3.11M
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.
